Biotech Values

[iwfal]

I think the risk of a bear market for stocks in general was a bigger factor in the timing of MNTA’s financing than concerns about Teva’s Lovenox.

If we knew they had to raise capital and it was just a matter of when then this argument would make sense to me. But if they have high confidence of being sole generic... then they would never have to raise capital in the forseeable future. So the market becomes immaterial. I think it is pretty unescapable that they have a significant worry that tL gets approved in the next few months.